Rocket Lab (RKLB) Stock: Wall Street Analysts Raise Price Targets Amid Mynaric A...
Rocket Lab (RKLB) stock receives $105 price target from Stifel amid multiple Buy ratings. Insiders sell shares while Mynaric acqui...
Robinhood (HOOD) Stock Climbs as Mizuho Boosts Price Target to $115 on Regulator...
Mizuho upgrades Robinhood (HOOD) to $115 as SEC removes $25K Pattern Day Trader rule. Learn why analysts expect revenue growth fro...
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump’s Psychedelic R...
Definium Therapeutics (DFTX) stock surged 13% premarket as Trump's Executive Order accelerates psychedelic drug research for menta...
Theriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Trial Re...
Theriva Biologics (TOVX) stock surged 63% after Phase 2b trial data revealed VCN-01 plus chemo improved survival in metastatic pan...
Salesforce (CRM) Stock Plunges 30% YTD as AI Threatens Traditional SaaS Revenue...
Salesforce (CRM) stock has fallen 30% in 2026 amid AI disruption fears. CEO Benioff counters with Agent Albert launch and Agentfor...
European Electric Vehicle Registrations Surge 29% Amid Rising Fuel Costs
European electric vehicle sales jumped 29% in Q1 2026, with March seeing 51% growth. Rising fuel prices from Iran conflict acceler...
Apple (AAPL) Stock: Goldman Sachs Holds $330 Target Days Before Q2 Earnings
Goldman Sachs keeps Buy rating on Apple (AAPL) stock with $330 target ahead of April 30 earnings, forecasting EPS beat despite DRA...
Nike Stock at Decade Low as Insider Buying Signals Possible Bottom
TLDR: Nike stock has fallen 76% from its 2021 all-time high of $179.10, now trading between $42 and $46 per share. China sales ar...
Netflix (NFLX) Stock Plunges 10% as Ark Invest’s Cathie Wood Doubles Down
Netflix (NFLX) stock dropped 10% on weak Q2 guidance and Reed Hastings' board exit. Cathie Wood bought the dip while Morgan Stanle...
Psychedelic Drug Stocks Explode After Trump’s FDA Fast-Track Executive Order
Trump executive order accelerates psychedelic drug approvals. AtaiBeckley surges 28%, Compass Pathways up 26% as FDA review times...